LRRK2 Regulates CPT1A to Promote β-Oxidation in HepG2 Cells

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 Sep 12

PMID 32916992

Citations 9

Authors

Chiao-Wei Lin

Yu-Ju Peng

Yuan-Yu Lin

Harry John Mersmann

Shih-Torng Ding

Affiliations

Soon will be listed here.

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is involved in lipid metabolism; however, the role of LRRK2 in lipid metabolism to affect non-alcoholic fatty liver disease (NAFLD) is still unclear. In the mouse model of NAFLD induced by a high-fat diet, we observed that LRRK2 was decreased in livers. In HepG2 cells, exposure to palmitic acid (PA) down-regulated LRRK2. Overexpression and knockdown of LRRK2 in HepG2 cells were performed to further investigate the roles of LRRK2 in lipid metabolism. Our results showed that β-oxidation in HepG2 cells was promoted by LRRK2 overexpression, whereas LRRK2 knockdown inhibited β-oxidation. The critical enzyme of β-oxidation, carnitine palmitoyltransferase 1A (CPT1A), was positively regulated by LRRK2. Our data suggested that the regulation of CPT1A by LRRK2 may be via the activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor α (PPARα). The overexpression of LRRK2 reduced the concentration of a pro-inflammatory cytokine, tumor necrosis factor α (TNFα), induced by PA. The increase in β-oxidation may promote lipid catabolism to suppress inflammation induced by PA. These results indicated that LRRK2 participated in the regulation of β-oxidation and suggested that the decreased LRRK2 may promote inflammation by suppressing β-oxidation in the liver.

Citing Articles

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis.

Ryu G, Laurel Yoon E, Kim W, Won Jun D Diagnostics (Basel). 2025; 15(3).

PMID: 39941272 PMC: 11817575. DOI: 10.3390/diagnostics15030342.

TIGAR exacerbates obesity by triggering LRRK2-mediated defects in macroautophagy and chaperone-mediated autophagy in adipocytes.

Zhang T, Linghu K, Tan J, Wang M, Chen D, Shen Y Autophagy. 2024; 20(8):1741-1761.

PMID: 38686804 PMC: 11262232. DOI: 10.1080/15548627.2024.2338576.

Mitochondrial CPT1A: Insights into structure, function, and basis for drug development.

Liang K Front Pharmacol. 2023; 14:1160440.

PMID: 37033619 PMC: 10076611. DOI: 10.3389/fphar.2023.1160440.

Changes in Liver Lipidomic Profile in G2019S- Mouse Model of Parkinson's Disease.

Corral Nieto Y, Yakhine-Diop S, Moreno-Cruz P, Manrique Garcia L, Pereira A, Morales-Garcia J Cells. 2023; 12(5).

PMID: 36899942 PMC: 10000529. DOI: 10.3390/cells12050806.

The HSF1-CPT1a Pathway Is Differentially Regulated in NAFLD Progression.

Breternitz W, Sandkuhler F, Grohmann F, Hampe J, Brosch M, Herrmann A Cells. 2022; 11(21).

PMID: 36359900 PMC: 9655849. DOI: 10.3390/cells11213504.

References

Pimenta A, Gaidhu M, Habib S, So M, Fediuc S, Mirpourian M . Prolonged exposure to palmitate impairs fatty acid oxidation despite activation of AMP-activated protein kinase in skeletal muscle cells. J Cell Physiol. 2008; 217(2):478-85. DOI: 10.1002/jcp.21520. View

Ai L, Xu Q, Wu C, Wang X, Chen Z, Su D . A20 Attenuates FFAs-induced Lipid Accumulation in Nonalcoholic Steatohepatitis. Int J Biol Sci. 2015; 11(12):1436-46. PMC: 4672001. DOI: 10.7150/ijbs.13371. View

Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans J, Daniels V . The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem. 2008; 283(24):16906-14. PMC: 2423262. DOI: 10.1074/jbc.M708718200. View

Srivastava R, Pinkosky S, Filippov S, Hanselman J, Cramer C, Newton R . AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012; 53(12):2490-514. PMC: 3494254. DOI: 10.1194/jlr.R025882. View

Polyzos S, Kountouras J, Mantzoros C . Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol. 2016; 42(2):92-108. DOI: 10.23736/S0391-1977.16.02563-3. View

Asgharpour A, Cazanave S, Pacana T, Seneshaw M, Vincent R, Banini B . A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016; 65(3):579-88. PMC: 5012902. DOI: 10.1016/j.jhep.2016.05.005. View

Gomez-Suaga P, Luzon-Toro B, Churamani D, Zhang L, Bloor-Young D, Patel S . Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet. 2011; 21(3):511-25. PMC: 3259011. DOI: 10.1093/hmg/ddr481. View

Tobita H, Sato S, Yazaki T, Mishiro T, Ishimura N, Ishihara S . Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver. Mol Med Rep. 2018; 17(5):6840-6846. DOI: 10.3892/mmr.2018.8673. View

Santhekadur P, Kumar D, Sanyal A . Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2017; 68(2):230-237. PMC: 5775040. DOI: 10.1016/j.jhep.2017.10.031. View

10.

Robinet P, Wang Z, Hazen S, Smith J . A simple and sensitive enzymatic method for cholesterol quantification in macrophages and foam cells. J Lipid Res. 2010; 51(11):3364-9. PMC: 2952578. DOI: 10.1194/jlr.D007336. View

11.

Baptista M, Dave K, Frasier M, Sherer T, Greeley M, Beck M . Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One. 2013; 8(11):e80705. PMC: 3828242. DOI: 10.1371/journal.pone.0080705. View

12.

Pierantonelli I, Svegliati-Baroni G . Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation. 2018; 103(1):e1-e13. DOI: 10.1097/TP.0000000000002480. View

13.

Kluss J, Mamais A, Cookson M . LRRK2 links genetic and sporadic Parkinson's disease. Biochem Soc Trans. 2019; 47(2):651-661. PMC: 6563926. DOI: 10.1042/BST20180462. View

14.

Guaitoli G, Raimondi F, Gilsbach B, Gomez-Llorente Y, Deyaert E, Renzi F . Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts. Proc Natl Acad Sci U S A. 2016; 113(30):E4357-66. PMC: 4968714. DOI: 10.1073/pnas.1523708113. View

15.

Russo I, Berti G, Plotegher N, Bernardo G, Filograna R, Bubacco L . Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells. J Neuroinflammation. 2015; 12:230. PMC: 4673731. DOI: 10.1186/s12974-015-0449-7. View

16.

Boddu R, Hull T, Bolisetty S, Hu X, Moehle M, Daher J . Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury. Hum Mol Genet. 2015; 24(14):4078-93. PMC: 4476452. DOI: 10.1093/hmg/ddv147. View

17.

Listenberger L, Han X, Lewis S, Cases S, Farese Jr R, Ory D . Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 2003; 100(6):3077-82. PMC: 152249. DOI: 10.1073/pnas.0630588100. View

18.

Palomer X, Pizarro-Delgado J, Barroso E, Vazquez-Carrera M . Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus. Trends Endocrinol Metab. 2018; 29(3):178-190. DOI: 10.1016/j.tem.2017.11.009. View

19.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

20.

Jin J, Zhang X, Lu Z, Perry D, Li Y, Russo S . Acid sphingomyelinase plays a key role in palmitic acid-amplified inflammatory signaling triggered by lipopolysaccharide at low concentrations in macrophages. Am J Physiol Endocrinol Metab. 2013; 305(7):E853-67. PMC: 3798699. DOI: 10.1152/ajpendo.00251.2013. View